PARP1 and familial pancreatic carcinoma: An example of such a study is the NIRAPANC trial enrolling metastatic pancreatic cancer patients with somatic and germline BRCA mutations, as well as other DNA repair deficiencies [43]. Notably in the COVID-19 era, PARP inhibitors, due to its per oral administration, has the added advantage of limiting patient in person healthcare visits and associated exposure, for instance compared to intravenously administered anti-cancer agents, especially with the availability of telemedicine follow-up.